Trials Sponsors Conditions Drugs Pricing

Conditions

Keywords

recurrent childhood acute lymphoblastic leukemiarecurrent childhood lymphoblastic lymphomarecurrent osteosarcomarecurrent childhood small noncleaved cell lymphomarecurrent childhood large cell lymphoma

Interventions

leucovorin calciumDrug

trimetrexate glucuronateDrug

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

AgeUp to 21 Years

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64)

DISEASE CHARACTERISTICS: * Histologic evidence of one of the following malignancies that has failed conventional therapy: * Acute lymphoblastic leukemia * Non-Hodgkin's lymphoma with bone marrow involvement * Osteogenic sarcoma * In vitro transport resistance to methotrexate demonstrated by bone marrow aspirate assay PATIENT CHARACTERISTICS: Age: * 21 and under at diagnosis Performance status: * ECOG 0-2 Life expectancy: * At least 8 weeks Hematopoietic: * Granulocytopenia allowed with bone marrow involvement * Thrombocytopenia allowed with bone marrow involvement * Anemia allowed with bone marrow involvement Hepatic: * (unless due to disease) * Bilirubin no greater than 2.0 mg/dL * AST no greater than 100 Renal: * Creatinine less than 1.5 mg/dL OR * Creatinine clearance at least 60 mL/min Other: * No other serious medical illness * Not pregnant or nursing * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * Prior bone marrow transplantation allowed Chemotherapy: * At least 1 week since prior intrathecal treatment * At least 2 weeks since prior systemic chemotherapy and recovered * At least 10 days for rapidly proliferating leukemia (i.e., WBC greater than 50,000) * No concurrent chemotherapy Endocrine therapy: * Not specified Radiotherapy: * Prior radiotherapy allowed and recovered * No concurrent radiotherapy Surgery: * Not specified

Sponsors & Collaborators

Memorial Sloan Kettering Cancer Center
Otherlead
National Cancer Institute (NCI)
NIHcollaborator

Study Sites (1)

Memorial Sloan-Kettering Cancer Center

New York, New York, 10021, United States

MeSH Terms

Conditions

LeukemiaLymphomaSarcomaPrecursor Cell Lymphoblastic Leukemia-LymphomaOsteosarcomaBurkitt LymphomaDendritic Cell Sarcoma, Interdigitating

Interventions

Leucovorintrimetrexate glucuronate

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesLymphoproliferative Disorders

Study Officials

Tanya Trippett, MD
Memorial Sloan Kettering Cancer Center
STUDY CHAIR

Study Design

Study Type: interventional
Phase: phase 2
Purpose: TREATMENT
Sponsor Type: OTHER

Study Record Dates

First Submitted

November 1, 1999

First Posted

January 27, 2003

Study Start

January 1996

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

June 2006

Actual (reported)

Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia, Osteosarcoma, or Non-Hodgkin's Lymphoma

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

Intervention Hierarchy (Ancestors)

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

Intervention Hierarchy (Ancestors)

Source record

Locations